- Report
- February 2024
- 30 Pages
Global
From €3090EUR$3,250USD£2,650GBP
- Report
- February 2024
- 175 Pages
Global
From €4753EUR$5,000USD£4,077GBP
- Report
- February 2024
- 150 Pages
Global
From €4516EUR$4,750USD£3,873GBP
- Report
- April 2024
- 30 Pages
Global
From €3090EUR$3,250USD£2,650GBP
From €6179EUR$6,500USD£5,300GBP
- Report
- February 2024
- 150 Pages
Global
From €4516EUR$4,750USD£3,873GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,223GBP
- Report
- January 2024
- 189 Pages
Global
From €7130EUR$7,500USD£6,116GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,223GBP
- Report
- March 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,384GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,384GBP
- Report
- August 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,569GBP
- Report
- February 2024
- 90 Pages
Middle East, Africa
From €4516EUR$4,750USD£3,873GBP
- Report
- February 2024
- 70 Pages
North America
From €4516EUR$4,750USD£3,873GBP
- Report
- February 2024
- 70 Pages
Europe
From €4516EUR$4,750USD£3,873GBP
- Report
- February 2024
- 70 Pages
Asia Pacific
From €4516EUR$4,750USD£3,873GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4516EUR$4,750USD£3,873GBP
- Report
- February 2024
- 70 Pages
United States
From €4516EUR$4,750USD£3,873GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4516EUR$4,750USD£3,873GBP
- Report
- August 2023
- 70 Pages
Latin America
From €4516EUR$4,750USD£3,873GBP
Empagliflozin is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to lower blood sugar levels. Empagliflozin is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Empagliflozin is marketed by several pharmaceutical companies, including Boehringer Ingelheim, Eli Lilly, and Merck. It is available in tablet form and is taken once daily. It is also available in combination with other diabetes medications, such as metformin and linagliptin. Show Less Read more